Cost-utility analysis of alemtuzumab versus natalizumab for the treatment of relapsing-remitting multiple sclerosis: Us payer perspective

Authors
Category Primary study
JournalValue in Health
Year 2016
This article has no abstract
Epistemonikos ID: 0cd96715e438ad321368e8d004af6d9e56c927c5
First added on: Feb 08, 2025